← Back to Home

New Maintenance Treatment Option for HER2-Positive Advanced Breast Cancer: FDA Approves Tukysa Triplet

Adding tucatinib to dual-antibody maintenance therapy extended median progression-free survival among trial patients from 16.3 to 24.9 months. However, whether it prolongs overall survival requires further follow-up, and the updated labeling also adds a boxed warning for serious hepatotoxicity.

By SURL BioNews

For patients with advanced breast cancer, prolonging disease stability after initial control is the central goal of the next phase of treatment. On October 7, 2026, the U.S. Food and Drug Administration (FDA) approved the oral targeted drug tucatinib (brand name Tukysa) in combination with trastuzumab and pertuzumab as maintenance therapy following induction treatment for adults with HER2-positive, unresectable locally advanced or metastatic breast cancer.

This approval brings tucatinib into a defined phase of treatment: patients first receive an induction regimen that includes chemotherapy, then enter maintenance treatment if their disease has not progressed. Tucatinib is a HER2-targeted tyrosine kinase inhibitor; the new combination adds this oral drug to two anti-HER2 antibodies to sustain cancer control.

The approval was based on HER2CLIMB-05, a randomized, double-blind, placebo-controlled trial involving 654 adult patients. Participants first received four to eight cycles of trastuzumab, pertuzumab, and taxane chemotherapy and entered the trial comparison only after investigators assessed that their disease had not progressed. The study allowed patients with or without brain metastases to participate; those with hormone receptor-positive disease could also continue endocrine therapy during maintenance.

Patients in both groups continued receiving trastuzumab and pertuzumab, with the addition of either tucatinib or placebo. Median progression-free survival was 24.9 months in the tucatinib group and 16.3 months in the control group, a difference of 8.6 months. The hazard ratio for disease progression or death was 0.64, corresponding to an approximately 36% reduction in relative risk during follow-up. This is a population-level comparison and cannot be interpreted to mean that every patient will gain the same additional period of disease stability.

The limits of the efficacy findings also need to be clear. Progression-free survival measures the time before disease progression or death and is not equivalent to overall survival. At the time of this analysis, overall survival data were not yet mature. The evidence therefore establishes a benefit in delaying progression but does not yet support a claim that patients live longer. The inclusion of patients with brain metastases also does not mean that the overall results above can, on their own, establish how effectively the treatment controls brain lesions.

Maintenance treatment may continue for a considerable time, making safety as important as efficacy. The U.S. prescribing information for Tukysa, updated in October 2026, adds a boxed warning for hepatotoxicity, stating that serious and even fatal liver injury may occur, particularly when treatment is restarted after discontinuation. The labeling requires liver function testing before and during treatment, with treatment interruption, dose reduction, or permanent discontinuation according to severity. Common adverse reactions with this maintenance combination also include diarrhea, musculoskeletal pain, nausea, fatigue, rash, and vomiting.

This approval provides a new option for prolonging disease control after induction treatment; it does not answer whether the preceding chemotherapy can be omitted. For eligible patients, the value of triplet maintenance therapy will depend on the extent of the delay in progression, the burden of ongoing treatment, and risks such as hepatotoxicity. Longer-term survival follow-up will fill a gap in the evidence that remains.

References

  1. Genome Web
  2. U.S. Food and Drug Administration
  3. U.S. Food and Drug Administration
  4. The ASCO Post